# ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

> **NCT07238075** · PHASE1 · RECRUITING · sponsor: **Adcytherix SAS** · enrollment: 290 (estimated)

## Conditions studied

- Advanced Malignancy
- Advanced Solid Cancers
- Metastatic Solid Tumors

## Interventions

- **DRUG:** ADCX-020

## Key facts

- **NCT ID:** NCT07238075
- **Lead sponsor:** Adcytherix SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-14
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-11-30
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07238075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07238075, "ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07238075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*